Hexo (TSX:HEXO) Stock Down 58% in 1 Year: Avoid it or Buy the Dip?

Hexo stocks have cratered in the last year. Learn why Aphria stock might be a better buy for you right now instead.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You may have noticed that Hexo (TSX:HEXO)(NYSE:HEXO) shares have cratered, dropping over 58% over one year. Many other cannabis company stocks have also experienced a decline in value, despite some recovery in the industry through the previous month.

While this is terrible news for any investors holding the stock, it may be an opportunity for you to buy the dip. The only question then remains: which marijuana stock will be the first to climb out of the rut?

What’s up with Hexo?

Hexo recently laid off 200 employees, including its chief manufacturing and chief marketing officers. Furthermore, guidance for the fiscal year 2020 was also withdrawn, which was enough to cause panic. The company explained in a news release that the delay was due to the private placement of $70 million worth of unsecured convertible debentures at an 8% rate.

Hexo CEO Sebastien St-Louis said that the move was made to rightsize the company to reach revenue expectations for fiscal year 2020. The CEO also blamed slow government approvals for derivative cannabis products and an anticipated pressure on pricing.

Although it has been more than a year of legalized use and sale of marijuana, the growth of the cannabis industry has been slow, mostly because of a black market. As a result, some provinces still have very few licensed stores, and getting approval is very difficult.

Silver linings for Hexo

Hexo does have some strategic advantages, in particular, some $230 million in net cash that makes this company especially attractive to investors. Add to that, Hexo has a joint venture with Molson Coors Canada, which provides an excellent distribution network and a background in consumer packaged goods.

A contract between the company and Quebec is also an added bonus that sets Hexo above other major marijuana companies. Considering that part of the reason for the glacial approval of licences is that provinces don’t share in tax revenue, and that Quebec holds almost a quarter of Canada’s population, Hexo had a lot more promise for long-term growth.

Which company has the most potential to come out on top?

There wasn’t a single cannabis stock that didn’t suffer from Hexo’s news release, but one company has shown amazing resilience — Aphria. The company announced its second consecutive profitable quarter with net income for Q1 of fiscal 2020, clocking in at $16.4 million up from $1 million for Q4 2019. Adjusted EBITDA came in at $1.3 million for the quarter, and share prices responded positively.

Following Hexo woes, APHA share prices also experienced some faltering but now seem to be stabilizing. The combination of excellent financials and an excellent outlook for fiscal year 2020 means that this is the company most likely to come out swinging first.

Foolish takeaway

If you’re looking for a company with the promise of upside after this dip, Aphria is likely a better choice than Hexo. Caution is warned for any stocks in marijuana right now, as investors have cooled off on the sector drastically.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »